Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Yizun Biopharmaceutical

Request full access

Yizun Biotech offers cell therapy solutions, including universal technologies for treating solid tumors and allogeneic cells

Hangzhou, ChinaFounded 2018Biotech & Life Sciences

About Yizun Biopharmaceutical

Yizun Biopharmaceutical (Zhejiang) Co., Ltd. is a clinical-stage biopharmaceutical entity established in 2018, concentrating on the development of cell therapies for solid tumors. The company was co-founded by Dr. Liu Lingfeng, an expert in immunotherapy, and Mr. Guo Xiaobin, who contributes extensive experience in investment and innovation incubation. Dr. Liu's background includes direct participation in CAR-T cell therapy development and clinical research at the Fred Hutchinson Cancer Research Center in the U.S., where he secured several international patents, some of which were licensed to Juno Therapeutics.

The company's core business revolves around the research and development of treatments for solid tumors and allogeneic cells, with a specific focus on accelerating the creation of allogeneic cell drugs for advanced liver cancer. Yizun Biopharmaceutical operates on a model that involves developing proprietary technology platforms and advancing product pipelines through clinical trials. It has established three primary technology platforms: CNK-T, VAC-T, and UT. The CNK-UT platform, in particular, demonstrated initial clinical efficacy in treating liver cancer in July 2020.

Revenue generation is intrinsically tied to the successful development and subsequent commercialization or licensing of its therapeutic products. The company has secured significant funding to support its operations, including a Pre-A round in June 2019 from Livzon Pharm, a Series A round in January 2022 co-led by VMS and Shenzhen Capital, and a Series A1 round in April 2024. These funds are allocated towards talent acquisition, R&D, clinical trials, and optimizing its technology platforms. To facilitate its research and production, the company operates a nearly 3,000-square-meter GMP production workshop and clinical transformation center in Hangzhou.

Source: Dealroom company data

At a glance

Status
Operational
Open positions
None listed
Dealroom signal
22.3/100
Industry
Health
Sub-industry
BioTechnology
Sector
Biotechnology, Spinout, Biotech and Pharma, DT and LS, science-based
Business model
Manufacturing
Client focus
B2B
Links
Website

Funding history

5 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
SERIES A✓Equity / VC Apr 2024 $14M $55M Tailong Investment · Tigeryeah Capital · Hangzhou Binjiang 5050 Fund ↗
SERIES A✓Equity / VC May 2022 $14M $55M Dingpei Group · Shenzhen Capital Group —
Showing the latest 2 of 5 recorded eventsBook a demo for the full funding history →

Growth signals

Yizun Biopharmaceutical website traffic

Latest recorded traffic for Yizun Biopharmaceutical is 230 monthly website visits.

Latest monthly visits230
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Yizun Biopharmaceutical in the Hangzhou ecosystem

Live from Dealroom

The Yizun Biopharmaceutical office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

12 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A10 investors entered at this stage

  • Livzon Pharmaceutical Group
  • VMS Capital
  • Shenzhen Capital Group
  • Tao Capital Partners
  • TEDA Venture Capital
  • Panacea Venture
  • Dingpei Group
  • Tailong Investment
  • Tigeryeah Capital
  • Hangzhou Binjiang 5050 Fund

Other known investors2 additional known investors

  • Fred Hutchinson Cancer Research Center
  • University of Washington
Founders Hidden — book a demo/100 quality score
Key operators Hidden — book a demo quality score
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
🇨🇳 China · Hangzhou HQ
Book a demo for the full country breakdown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Yizun Biopharmaceutical on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Yizun Biopharmaceutical’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.